INVESTORS

Press Releases

Year

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

December 18, 2024

- Approval in Hong Kong marks the first clinical trial application clearance of an in vivo gene editing approach for chronic hepatitis B in Hong Kong and the second CTA approval for PBGENE-HBV in 2024 - ELIMINATE-B is a global, multi-site study now actively recruiting patients; expected to report...

Precision BioSciences to Participate in Upcoming November Investor Conferences

November 21, 2024

DURHAM, N.C. --(BUSINESS WIRE)--Nov. 21, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the...

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

November 15, 2024

– PBGENE-HBV preclinical data reinforce safety profile and potential to deliver a functional cure for chronic hepatitis B, supporting advancement into first-in-human clinical study – – Phase 1 dose escalation and expansion trial, ELIMINATE-B, designed to assess safety and efficacy measured by...

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

November 4, 2024

- Received approval for first Clinical Trial Application to advance PBGENE-HBV into first-in-human trials for treatment of chronic hepatitis B; additional global regulatory applications pending approval - Opened PBGENE-HBV phase 1 clinical program in Moldova ; patient screening underway with...

Precision BioSciences to Report Third Quarter Results on November 4, 2024

October 29, 2024

DURHAM, N.C. --(BUSINESS WIRE)--Oct. 29, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will publish financial...

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

October 28, 2024

DURHAM, N.C. --(BUSINESS WIRE)--Oct. 28, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced it will host a Hepatitis B...

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

October 24, 2024

- Stimulating gene editing by homology-directed repair (HDR) has the potential advantage of being able to achieve any type of edit, including gene insertion - ARCUS approach potentially offers broader therapeutic than current gene editing modalities for diseases that require a gain in function...

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

October 24, 2024

- Clinical Trial Application accepted in Moldova with additional regulatory applications pending approval - PBGENE-HBV is the first in vivo gene editing program for chronic hepatitis B virus to move into global clinical trials - Company to host investor event highlighting clinical candidate safety...

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

October 21, 2024

DURHAM, N.C. --(BUSINESS WIRE)--Oct. 21, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the...

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress

October 16, 2024

DURHAM, N.C. --(BUSINESS WIRE)--Oct. 16, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL) is an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion which is necessary for...

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Next page
Last page

Displaying 1 - 10 of 45

Investors

Events & Presentations
Press Releases
Corporate Deck
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Sustainability
Investor FAQs

Investor Tools

Print Page
Email Alerts
Contact IR
RSS Feeds

INVESTORS

Press Releases

Investors

Investor Tools

Contact Info

Learn More

Policies